Maporal Virus as a Surrogate for Pathogenic New World Hantaviruses and its Inhibition by Favipiravir | Zendy

Kristin K. Buys | Zendy; KieHoon Jung | Zendy; Donald F. Smee | Zendy; Yousuke Furuta | Zendy; Brian B. Gowen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maporal Virus as a Surrogate for Pathogenic New World Hantaviruses and its Inhibition by Favipiravir

Author(s) -

Kristin K. Buys,

KieHoon Jung,

Donald F. Smee,

Yousuke Furuta,

Brian B. Gowen

Publication year - 2011

Publication title -

antiviral chemistry and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.919

H-Index - 51

eISSN - 2040-2066

pISSN - 0956-3202

DOI - 10.3851/imp1729

Subject(s) - favipiravir , hantavirus , virology , hantavirus infection , biology , ribavirin , virus , lassa fever , bunyaviridae , arbovirus , medicine , disease , infectious disease (medical specialty) , hepatitis c virus , pathology , covid-19

Pathogenic hantaviruses geographically distributed in the Old World cause haemorrhagic fever with renal syndrome (HFRS), whereas New World hantaviruses are the aetiological agents of hantavirus cardiopulmonary syndrome (HCPS). Ribavirin, a drug associated with toxicities, is presently indicated for treatment of HFRS, whereas treatment of the more frequently lethal HCPS is limited to supportive care. Because of the need for safe and effective antivirals to treat severe hantaviral infections, we evaluated favipiravir (T-705) against Dobrava and Maporal viruses as representative Old World and New World hantaviruses, respectively. Dobrava virus causes HFRS in Europe. Maporal virus (MPRLV), recently isolated from western Venezuela, is phylogenetically similar to Andes virus, the principal cause of HCPS in Argentina.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research